A new vaccine that promises to help smokers quit by gradually reducing their satisfaction from cigarettes is the focus of a national study at UCLA. Whereas nicotine patches or chewing gum deliver low doses of nicotine to the brain, the vaccine-NicVAX-works by producing antibodies that bind to nicotine in the body. The resulting nicotine molecules are too large to reach the brain, in effect depriving the smoker of their pleasurable experience.
Audience-funded nonprofit news
Next Up:
0:00
0:00
-
Listen Listen
-
Listen Listen